Icon

DITROPAN (nda017577)- (5MG)

OXYBUTYNIN CHLORIDE JANSSEN PHARMS
5MG
No No
Expired Expired
None None
None No
DITROPAN® (oxybutynin chloride) is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria).
13 0 10
Total Other Developers None
Drugs with Suitability Yes
5MG ** ** - - 10
NDA Sales Available Total Generic Sales Available
No 11
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** *** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** **** ****** *** ************ ******** ** *********** *, ********** ****** ***., ********, ****, ******** (***) ***
****** ****** ***** **** ******-***** ************, *** *********** *** * ******** **, ******, ******** (**) *****-****, ****** ****** (***) ***
****** ****** ***** **** ******-***** ************, *** *********** ***** **** *** *, ********, ********* (**) *****-****, ****** ****** (***) ***
****** ****** ***** **** ******-***** ************, *** *********** **** ******** ***** *, ***** *****, ********* (**) *****-****, ****** ****** (***) ***
****** ******* ****** ******** ***** ** *** */*/* ******** ************ *********** ***** ******** ****., *********, ***** ******** (**) *****, ****** ****** (***) ***
****** ******* ****** ******** ***** ** *** */*/* ******** ************ *********** **** ******** ****., *********, ***** ******** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* ******, *** *********** * *** ***** **, ******** *****, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ***** ****** *** *********** *** *** *** ********* ** ***** *, *, *-* & *, **********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ****** ***** ****** *** *********** *** *** ************ **, **********, *** ****** (**) *****, ****** ****** (***) ***
****** ***** *** ***-****, ***. *********** *** ***** **., *******, ************ (**) *****, ****** ****** (***) ***
****** ******** ****** ******** ****** *** *********** ** **** *****, **** *******, *** ****** (**) *****, ****** ****** (***) ***
****** ******** ****** ******** ****** *** *********** ** **** *****, **** *******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ***** *************** *** *********** * ***** ***** *****, ********, *** ****** (**) *****, ****** ****** (***) ***
****** ******* ********** *** *********** **** *****-***** **, **** ** ******, *****, *.*. *** *****, ****** **** ******** (***) ***
****** ******* ****** ******* ****** ******* ******* *********** ** **/*,******************, ********* *****, ****** *****, *********, ********* ******, ***** (***) ***
****** **** ************ ******* ************ ******* *********** *** ****-* **** **. *-**/*, *-***, & *-***, **** **. **, *** ********, ***** ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.